Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:MRKR NASDAQ:PEPG NASDAQ:PMN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.68+0.2%$0.92$0.63▼$10.80$95.09M1.713.11 million shs264,553 shsMRKRMarker Therapeutics$1.44+1.8%$1.47$0.81▼$4.07$23.92M1.44208,185 shs11,146 shsPEPGPepGen$1.44+4.0%$1.66$1.01▼$7.80$99.26M1.931.11 million shs67,810 shsPMNPromis Neurosciences$9.84+1.1%$11.03$6.27▼$39.75$88.29M-0.19111,753 shs715 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+3.32%-13.95%-30.76%-50.82%-93.17%MRKRMarker Therapeutics-3.42%-0.70%-3.42%+2.92%-18.02%PEPGPepGen+2.22%-4.83%-21.59%-78.06%-9.21%PMNPromis Neurosciences+0.31%-4.04%-0.92%-51.52%-22.85%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.68+0.2%$0.92$0.63▼$10.80$95.09M1.713.11 million shs264,553 shsMRKRMarker Therapeutics$1.44+1.8%$1.47$0.81▼$4.07$23.92M1.44208,185 shs11,146 shsPEPGPepGen$1.44+4.0%$1.66$1.01▼$7.80$99.26M1.931.11 million shs67,810 shsPMNPromis Neurosciences$9.84+1.1%$11.03$6.27▼$39.75$88.29M-0.19111,753 shs715 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma+3.32%-13.95%-30.76%-50.82%-93.17%MRKRMarker Therapeutics-3.42%-0.70%-3.42%+2.92%-18.02%PEPGPepGen+2.22%-4.83%-21.59%-78.06%-9.21%PMNPromis Neurosciences+0.31%-4.04%-0.92%-51.52%-22.85%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AMRKRMarker Therapeutics 2.25Hold$10.00596.86% UpsidePEPGPepGen 2.67Moderate Buy$11.60708.36% UpsidePMNPromis Neurosciences 2.75Moderate Buy$26.50169.20% UpsideCurrent Analyst Ratings BreakdownLatest MRKR, PEPG, AIFC, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026PMNPromis Neurosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/2/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/20/2026PMNPromis Neurosciences Brookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.004/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $5.003/27/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M3.83N/AN/A$9.07 per share0.07MRKRMarker Therapeutics$3.55M6.74N/AN/A$1.01 per share1.42PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/AMRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%8/13/2026 (Estimated)PEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)PMNPromis Neurosciences-$39.72M-$14.51N/AN/AN/AN/A-237.99%-151.04%8/12/2026 (Estimated)Latest MRKR, PEPG, AIFC, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 million5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/18/2026Q4 2025MRKRMarker Therapeutics-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82MRKRMarker TherapeuticsN/A4.794.79PEPGPepGenN/A14.9814.98PMNPromis NeurosciencesN/A9.929.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%MRKRMarker Therapeutics22.39%PEPGPepGen58.01%PMNPromis Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%MRKRMarker Therapeutics5.70%PEPGPepGen1.30%PMNPromis Neurosciences1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/AMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionablePEPGPepGen3069.17 million68.27 millionNot OptionablePMNPromis Neurosciences58.97 million8.83 millionNot OptionableMRKR, PEPG, AIFC, and PMN HeadlinesRecent News About These CompaniesPromis Neurosciences (NASDAQ:PMN) Upgraded by Wall Street Zen to Sell RatingMay 31, 2026 | americanbankingnews.comProMIS Neurosciences to Participate in Upcoming Conferences in JuneMay 28, 2026 | globenewswire.comProMIS Neurosciences (PMN) Receives a Buy from GuggenheimMay 20, 2026 | theglobeandmail.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | finanznachrichten.deProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate HighlightsMay 12, 2026 | globenewswire.comInsider Buying: Promis Neurosciences (NASDAQ:PMN) Director Buys 4,000 Shares of StockApril 24, 2026 | insidertrades.comProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 13, 2026 | newsfilecorp.comNProMIS Neurosciences (PMN) price target decreased by 57.76% to 35.06March 28, 2026 | msn.comProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | finanznachrichten.deProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate HighlightsMarch 25, 2026 | globenewswire.comProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer's Disease/Parkinson's Disease 2026 International Conference (AD/PD™)March 18, 2026 | globenewswire.comAlly Bridge Group NY LLC Increases Holdings in Promis Neurosciences $PMNMarch 15, 2026 | defenseworld.netDInsider Buying: Promis Neurosciences (NASDAQ:PMN) Director Buys 1,000 Shares of StockMarch 5, 2026 | insidertrades.comPromis Neurosciences (NASDAQ:PMN) Insider Buys $25,005.15 in StockFebruary 24, 2026 | insidertrades.comInsider Buying: Promis Neurosciences (NASDAQ:PMN) Major Shareholder Acquires 700,741 Shares of StockFebruary 6, 2026 | insidertrades.comProMIS Neurosciences Inc.: ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 4, 2026 | finanznachrichten.deProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026February 4, 2026 | markets.businessinsider.comProMIS Neurosciences (PMN) price target decreased by 22.70% to 105.95February 4, 2026 | msn.comProMIS Neurosciences Announces Up to $175 Million Private Placement FinancingJanuary 30, 2026 | globenewswire.comPromis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy†from BrokeragesJanuary 19, 2026 | defenseworld.netDNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRKR, PEPG, AIFC, and PMN Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.68 +0.00 (+0.19%) As of 10:27 AM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Marker Therapeutics NASDAQ:MRKR$1.44 +0.03 (+1.77%) As of 10:36 AM Eastern This is a fair market value price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.PepGen NASDAQ:PEPG$1.44 +0.06 (+3.99%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Promis Neurosciences NASDAQ:PMN$9.84 +0.10 (+1.07%) As of 10:42 AM Eastern This is a fair market value price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FuelCell Energy Just Got a Wake-Up Call From Wall Street Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Corning Is Paving AI's Future With Glass Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
